reports
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1...
Solid Biosciences Provides Interim Positive Clinical Update on Phase 1/2 INSPIRE DUCHENNE Trial - 40 participants have been dosed with SGT-003 in the INSPIRE DUCHENNE trial to date - - Robust microdystrophin expression with consistent mechanistic evidence of dystrophin associated protein complex (DAPC) restoration and improvements in muscle integrity, including stabilization and improvement in cardiac function (LVEF) observed after treatment with SGT-003 - - SGT-003 continued to demonstrate an encouraging safety profile and has been generally well tolerated in the 40 participants dosed as...
- Jonathan Moreland
VKTX VIKING THERAPEUTICS
ROCK GIBRALTAR INDUSTRIES INC.
PSTG PURE STORAGE INC. CLASS A
MNKD MANNKIND CORP.
MLAB MESA LABORATORIES INC.
FSS FEDERAL SIGNAL CORPORATION
AOSL ALPHA & OMEGA SEMICONDUCTOR
EVR EVERCORE INC CLASS A
PLBC PLUMAS BANCORP
SSP THE E.W. SCRIPPS COMPANY
TCPC BLACKROCK TCP CAPITAL CORP.
EML THE EASTERN COMPANY
TSLX SIXTH STREET SPECIALTY LENDING
ADV INC.
EOSE ADVANTAGE SOLUTIONS INC (A)
BLCO EOS ENERGY ENTERPRISES INC (A)
BAUSCH + LOMB CORP
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results an...
Editas Medicine Announces Fourth Quarter and Full Year 2025 Results and Business Updates Lead candidate, EDIT-401, which demonstrated >90% mean LDL-C reduction in preclinical studies, remains on track for IND/CTA submission by mid-2026 Preparing to initiate Company’s first-in-human clinical trial in HeFH patients, with early human proof-of-concept data on track for year-end 2026 Strong cash position with cash runway into the third quarter of 2027 CAMBRIDGE, Mass., March 09, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on dev...
- Jonathan Moreland
CSGP COSTAR GROUP INC
XRAY DENTSPLY SIRONA INC.
TCBI TEXAS CAPITAL BANCSHARES INC.
SFM SPROUTS FARMERS MARKETS INC.
NWBI NORTHWEST BANCSHARES INC.
MYGN MYRIAD GENETICS INC.
FFIN FIRST FINANCIAL BANKSHARES INC
COTY COTY INC. CLASS A
NXRT NEXPOINT RESIDENTIAL TRUST INC.
WHF WHITEFIELD
ORN ORION GROUP HOLDINGS
THO THOR INDUSTRIES INC.
TTEC TELETECH HOLDINGS
HOG INC.
GO HARLEY-DAVIDSON INC.
ALT GROCERY OUTLET HOLDING
TSLX ALTIMMUNE INC
VERX SIXTH STREET SPECIALTY LENDING
ADV INC.
TKNO VERTEX
AIRS INC.
QSI ADVANTAGE SOLUTIONS INC (A)
FRST ALPHA TEKNOVA
TCBX INC.
EBC AIRSCULPT TECHNOLOGIES INC
NBBK QUANTUM-SI INC
MXF PRIMIS FINANCIAL CORP
LYEL THIRD COAST BANCSHARES INC
EASTERN BANKSHARES INC
NB BANCORP INC.
THE MEXICO FUND
INC.
LYELL IMMUNOPHARMA INC.
Solid Biosciences Announces Oversubscribed $240 Million Private Placem...
Solid Biosciences Announces Oversubscribed $240 Million Private Placement CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced that it has entered into a securities purchase agreement with a select group of institutional accredited investors for an approximately $240 million private placement, before deducting placement agent fees and offering expenses, which is expected to close on or about March 9, 2026, subject to the satisfacti...
Solid Biosciences to Present at the 2026 Muscular Dystrophy Associatio...
Solid Biosciences to Present at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Conference CHARLESTOWN, Mass., March 06, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced presentations on SGT-003, its next-generation investigational gene therapy for Duchenne muscular dystrophy, and SGT-212, its dual-route investigational gene therapy for Friedreich’s ataxia (FA), at the 2026 Muscular Dystrophy Association (MDA) Clinical & Scientific Confe...
Teledyne e2v stellt die Perciva™ 5D-Kamera vor: Okklusionsfreie 3D-Bil...
Teledyne e2v stellt die Perciva™ 5D-Kamera vor: Okklusionsfreie 3D-Bildaufnahme für Industrie, Einzelhandel und Robot Vision GRENOBLE, Frankreich, March 05, 2026 (GLOBE NEWSWIRE) -- Teledyne e2v, ein Unternehmen der Teledyne Technologies [NYSE: TDY] und weltweit führend in der Bildverarbeitungstechnologie, gibt die Markteinführung der -Kamera bekannt, einer bahnbrechenden Innovation im Bereich der Bildgebung, die hochwertige 3D-Bildverarbeitung auf kurze Distanz kostengünstig, zuverlässig und einfach zu integrieren macht. Die meisten Industriekameras nehmen nur 2D-Bilder auf, doch viele ...
Teledyne e2v Introduces Perciva™ 5D Camera: Occlusion-free 3D Vision f...
Teledyne e2v Introduces Perciva™ 5D Camera: Occlusion-free 3D Vision for Industrial, Retail, and Robotic Imaging GRENOBLE, France, March 05, 2026 (GLOBE NEWSWIRE) -- Teledyne e2v, a Teledyne Technologies [NYSE: TDY] company and global innovator of imaging solutions, announces the launch of the camera, a breakthrough imaging innovation designed to make high-quality short-range 3D vision cost-effective, reliable, and easy to integrate. Most industrial cameras only capture 2D images, yet many applications increasingly require depth perception at close and very-close distances. Perciva 5D d...
Insight Molecular Diagnostics Completes Key Milestones Advancing Graft...
Insight Molecular Diagnostics Completes Key Milestones Advancing GraftAssureDx Toward FDA Submission Three-site reproducibility study completed by Tampa General Hospital, Mayo Clinic, and Baylor Scott & White HealthSufficient clinical samples collected to support statistical analysis and FDA submissionCompany achieved final ISO 13485 certification on Feb. 26, enabling U.K. and E.U. regulatory submissions NASHVILLE, Tenn., March 03, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx”) today announced that in February the company completed several major miles...
Advantage Solutions Reports Fourth Quarter and Full Year 2025 Results
Advantage Solutions Reports Fourth Quarter and Full Year 2025 Results Strong cash flow performance resulted in ending the quarter with $241 million of cash, up $40 million sequentially Completion of non-core divestitures, planned debt refinancing and upcoming reverse stock split Expect flat to up low-single digit revenue growth in 2026, Adjusted EBITDA flat to down mid-single digits ST. LOUIS, March 03, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage,” “Advantage Solutions,” the “Company,” “we,” or “our”), a leading business solutions provider to ...
- Wedbush Research
TTWO TAKE-TWO INTERACTIVE SOFTWARE INC.
SIMON SILICON MOTION TECHNOLOGY CORPORATION SPONSORED ADR
PSTG PURE STORAGE INC. CLASS A
NVDA NVIDIA CORPORATION
NTAP NETAPP INC.
MU MICRON TECHNOLOGY INC.
INTC INTEL CORPORATION
GOOGL ALPHABET INC. CLASS A
FB FACEBOOK INC. CLASS A
AXTI AXT INC.
ASND ASCENDIS PHARMA A/S SPONSORED ADR
2330 TAIWAN SEMICONDUCTOR MANUFACTURING CO. LTD.
2303 UNITED MICROELECTRONICS CORP.
NTLA INTELLIA THERAPEUTICS INC.
MDB MONGODB INC. CLASS A
AMZN AMAZON.COM INC.
AMD ADVANCED MICRO DEVICES INC.
AAPL APPLE INC.
RCKT ROCKET PHARMACEUTICALS
MSFT MICROSOFT CORPORATION
CRWD CROWDSTRIKE HOLDINGS INC. CLASS A
SMCI SUPER MICRO COMPUTER
LRMR INC.
NUVB LARIMAR THERAPEUTICS INC
STX NUVATION BIO INC (A)
QUBT SEAGATE TECHNOLOGY HLDGS PLC
GFS QUANTUM COMPUTING INC
S GLOBALFOUNDRIES INC
RGTI SENTINELONE INC
TYRA RIGETTI COMPUTING INC
APGE TYRA BIOSCIENCES INC
NATL APOGEE THERAPEUTICS INC
RBRK NCR ATLEOS CORPORATION
RUBRIK INC
- Yun Zhong
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule ...
Solid Biosciences Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CHARLESTOWN, Mass., March 02, 2026 (GLOBE NEWSWIRE) -- Solid Biosciences Inc. (Nasdaq: SLDB) (the “Company”), a life sciences company developing precision genetic medicines for neuromuscular and cardiac diseases, today announced grants of 17,600 restricted stock units (“RSUs”) to one newly hired employee. The RSUs vest in four equal installments on each one-year anniversary of the grant date until the fourth anniversary of the grant date. Vesting of the equity awards is subject to the applicable employee’s c...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences...
Cardiff Oncology to Participate in Three Upcoming Investor Conferences SAN DIEGO, Feb. 26, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that company management will participate in three upcoming investor conferences in March 2026. TD Cowen 46th Annual Health Care ConferenceDate: 03/04/26 Barclays 28th Annual Global Healthcare ConferenceDate: 03/10/26 Leerink Partners Global Healthcare Conference 2026Date: 03/11/26 Interested part...
Advantage Solutions Appoints Thomas Turner and Frank Yao to Board of D...
Advantage Solutions Appoints Thomas Turner and Frank Yao to Board of Directors ST. LOUIS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) announced the appointments of Thomas Turner and Xiaofeng "Frank" Yao to its Board of Directors, effective as of February 20, 2026. About Thomas Turner Turner currently serves as Senior Managing Director at CVC Capital Partners (U.S.) Inc., where he has been a member of the Capital Markets team since September 2022. Prior to CVC, Turner held Managing Director roles at Apollo Global Management, Inc. and Bank of America Merrill L...
Cardiff Oncology Reports Full Year 2025 Results and Provides Business ...
Cardiff Oncology Reports Full Year 2025 Results and Provides Business Update Reported positive update from Phase 2 CRDF-004 trial in first-line RAS-mutated mCRC, with the 30 mg onvansertib + FOLFIRI/bev arm demonstrating:• Robust ORR of 72.2% (vs 43.2% with combined SoC of FOLFOX/bev and FOLFIRI/bev)• Significant improvement in PFS over combined SoC (HR: 0.37, p
Advantage Solutions Inc. Announces Early Results of Previously Announc...
Advantage Solutions Inc. Announces Early Results of Previously Announced Exchange Offer and Consent Solicitation Holders of greater than 99% of the aggregate principal amount of the Existing Notes have already tendered and delivered their consents. Holders of greater than 99% of the aggregate principal amount of the Existing Term Loans have already agreed to participate in the Term Loans Transactions. ST. LOUIS, Feb. 24, 2026 (GLOBE NEWSWIRE) -- Advantage Solutions Inc. (NASDAQ: ADV) (“Advantage Solutions”), a leading provider of business solutions to consumer goods manufacturers and re...
Editas Medicine to Participate in Upcoming Investor Conferences
Editas Medicine to Participate in Upcoming Investor Conferences CAMBRIDGE, Mass., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company focused on developing transformative medicines for serious diseases, today announced that management will participate in the following upcoming investor conferences in March: TD Cowen 46th Annual Health Care ConferenceFormat: Fireside Chat Date: Monday, March 2Time: 10:30 a.m. ETLocation: Boston, MA Barclays 28th Annual Global Healthcare ConferenceFormat: Fireside Chat Date: Thursday, March 12Time: 8:0...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.